{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:22:08Z","timestamp":1794270128810,"version":"4.9.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100019771","name":"European Union's Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ijantimicag.2026.107907","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:44:22Z","timestamp":1783147462000},"page":"107907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world evaluation of HIV-1 reservoir and resistance in virologically suppressed people after 52 weeks of treatment with long-acting cabotegravir + rilpivirine"],"prefix":"10.1016","volume":"67","author":[{"given":"Greta","family":"Marchegiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-1980","authenticated-orcid":false,"given":"Francesco Paolo","family":"Antonucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Bertoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Bellocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4932-5344","authenticated-orcid":false,"given":"Daniele","family":"Spalletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1713-8682","authenticated-orcid":false,"given":"Luca","family":"Carioti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Eizadi-Moghadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Narducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vergori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4924-329X","authenticated-orcid":false,"given":"Omar","family":"El Khalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Armenia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Lo Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6228-1114","authenticated-orcid":false,"given":"Maria Mercedes","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijantimicag.2026.107907_bib0001","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11904-025-00741-4","article-title":"Long-Acting injectable antiretroviral therapy for treatment of human immunodeficiency virus: a review","volume":"22","author":"Johnson","year":"2025","journal-title":"Current HIV\/AIDS rep"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0002","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/QAD.0000000000003025","article-title":"Week 96 extension results of a phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment","volume":"36","author":"Swindells","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0003","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/cid\/ciad020","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study","volume":"76","author":"Overton","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0004","article-title":"Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0005","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3390\/v17081108","article-title":"Safety, tolerability, and metabolic effects of long-acting cabotegravir and rilpivirine in HIV care: a comprehensive review","volume":"17","author":"Bottanelli","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0006","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-13805-7","article-title":"Acceptability of long acting injectable antiretroviral therapy in people living with HIV at a large single centre","volume":"15","author":"Arsuffi","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0007","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00052-22","article-title":"Genotypic resistance testing of HIV-1 DNA in peripheral blood mononuclear cells","volume":"35","author":"Chu","year":"2022","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0008","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaf161","article-title":"Utilizing HIV proviral DNA to assess for the presence of HIV drug resistance","volume":"81","author":"Wensing","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0009","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/QAD.0000000000004040","article-title":"Proviral HIV DNA sequencing to inform suitability for long-acting injectable cabotegravir\/rilpivirine","volume":"39","author":"Alagaratnam","year":"2025","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0010","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0011","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1473-3099(24)00289-5","article-title":"Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial","volume":"24","author":"Kityo","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0012","doi-asserted-by":"crossref","first-page":"ofaf368","DOI":"10.1093\/ofid\/ofaf368","article-title":"Optimizing the use of cabotegravir plus rilpivirine long-acting therapy in HIV care: evidence, implementation, and unanswered questions","volume":"12","author":"Geretti","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0013","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1128\/JVI.79.3.1975-1980.2005","article-title":"G\u2192A hypermutation in protease and reverse transcriptase regions of human Immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo","volume":"79","author":"Kieffer","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0014","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cmi.2015.10.004","article-title":"Contribution of APOBEC3G\/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants","volume":"22","author":"Noguera-Julian","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2023.105551","article-title":"Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals","volume":"168","author":"Armenia","year":"2023","journal-title":"J Clin Virol"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225352","article-title":"Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences","volume":"15","author":"Tzou","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0017","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/hiv.70057","article-title":"Long-acting injectable cabotegravir and rilpivirine in observational cohort studies: a systematic review on virological failure, resistance and re-suppression outcomes in virally suppressed individuals living with HIV","volume":"26","author":"Ring","year":"2025","journal-title":"HIV Med"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0018","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/cid\/ciae631","article-title":"Virologic failure and emergent integrase strand transfer inhibitor drug resistance with long-acting cabotegravir for HIV treatment: a meta-analysis","volume":"81","author":"Perez Navarro","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0019","doi-asserted-by":"crossref","DOI":"10.1177\/23259582241269837","article-title":"Patient participant perspectives on implementation of long-acting cabotegravir and rilpivirine: results from the cabotegravir and rilpivirine implementation study in European locations (CARISEL) study","volume":"23","author":"Gutner","year":"2024","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105427","article-title":"Genotypic correlates of resistance to the HIV-1 strand transfer integrase inhibitor cabotegravir","volume":"208","author":"Rhee","year":"2022","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(25)00131-6","article-title":"Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process","volume":"12","author":"Orkin","year":"2025","journal-title":"Lancet HIV"},{"issue":"6","key":"10.1016\/j.ijantimicag.2026.107907_bib0022","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/cid\/ciag046","article-title":"Virological failure on long-acting injectable cabotegravir and rilpivirine: an analysis of subtypes, drug levels, resistance, and therapeutic implications","volume":"82","author":"Mazzitelli","year":"2026","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0023","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1128\/CMR.00015-16","article-title":"Total HIV-1 DNA, a marker of viral reservoir dynamics with clinical implications","volume":"29","author":"Avettand-F\u00e8no\u00ebl","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0024","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/jac\/dkaa058","article-title":"Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir\/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study","volume":"75","author":"Lombardi","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0025","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiae405","article-title":"In-depth analysis of the HIV reservoir confirms effectiveness and safety of dolutegravir\/lamivudine in a phase 4 randomized controlled switch trial (RUMBA)","volume":"231","author":"De Scheerder","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0026","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/diagnostics12010039","article-title":"Quantification of total HIV DNA as a marker to measure viral reservoir: methods and potential implications for clinical practice","volume":"12","author":"Belmonti","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0027","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/hiv.70030","article-title":"Immune profiles and HIV reservoir in people switching to long-acting cabotegravir\/rilpivirine: findings from a real-life prospective study","volume":"26","author":"Mazzitelli","year":"2025","journal-title":"HIV Med"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0028","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/QAD.0b013e3282f5e07a","article-title":"Sequence editing by apolipoprotein B RNA-editing catalytic component-B and epidemiological surveillance of transmitted HIV-1 drug resistance","volume":"22","author":"Gifford","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0029","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1128\/JVI.00495-16","article-title":"HIV-1 protease, reverse transcriptase, and integrase variation","volume":"90","author":"Rhee","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0030","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/QAD.0000000000002850","article-title":"Drug resistance mutations in HIV provirus are associated with defective proviral genomes with hypermutation","volume":"35","author":"Li","year":"2021","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.ijantimicag.2026.107907_bib0031","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/00126334-200010001-00002","article-title":"Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review","volume":"25","author":"Graham","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0032","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae282","article-title":"Cabotegravir + rilpivirine long-acting: overview of injection guidance, injection site reactions, and best practices for intramuscular injection administration","volume":"11","author":"Teichner","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107907_bib0033","doi-asserted-by":"crossref","first-page":"ofad217","DOI":"10.1093\/ofid\/ofad217","article-title":"Gynoid fat distribution and adipocyte trapping may explain virological failure with intramuscular long-acting cabotegravir and rilpivirine","volume":"10","author":"De Malliard","year":"2023","journal-title":"Open Forum Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926001949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926001949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:37:16Z","timestamp":1794267436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857926001949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0924857926001949"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107907","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world evaluation of HIV-1 reservoir and resistance in virologically suppressed people after 52 weeks of treatment with long-acting cabotegravir + rilpivirine","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107907","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107907"}}